# Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients

> **NCT00228020** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 212 (actual)

## Conditions studied

- Pediatric Kidney Transplantation

## Interventions

- **DRUG:** basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)
- **DRUG:** MMF, cyclosporine, steroids

## Key facts

- **NCT ID:** NCT00228020
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2006-01
- **Final completion:** —
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2010-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228020, "Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00228020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*